Andrew Dunn

@AndrewE_Dunn

Pharma and biotech reporter for Say hello: adunn@businessinsider.com

Washington, DC
Vrijeme pridruživanja: ožujak 2015.
Rođen/a 11. srpnja

Tweetovi

Blokirali ste korisnika/cu @AndrewE_Dunn

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AndrewE_Dunn

  1. Prikvačeni tweet
    21. sij

    The fabled PERSONAL NEWS tweet: Today’s my first day as Business Insider’s pharma and biotech reporter! So excited to keep covering the industry as part of BI’s healthcare team — get in touch, everyone.

    Poništi
  2. 31. sij

    Simple — yet stunning — graphic to see. # of confirmed cases of coronavirus in China, per daily situation reports from WHO. Just under 25,000 cases if you add suspected cases in China.

    Poništi
  3. proslijedio/la je Tweet

    This week's Dispensed is out! In it: - So much on + the primary care biz overall - 's insights from biotech/pharma earnings - my deep-dive on 's partnership strategy Subscribe!

    Poništi
  4. 31. sij

    Just published in The Lancet: a new model by U. of Hong Kong researchers says 75,800 individuals in Wuhan may have been infected w/ coronavirus as of Jan. 25. Also says multiple major Chinese cities may have enough cases for local epidemics.

    Poništi
  5. 31. sij

    Amgen's recent R&D on kidney disease hasn't brought "game-changing innovation," CEO Bob Bradway said yesterday, so is turning to M&A/BD to bring in external assets. up 8% today, a top Wall Street takeout target working in the kidney space.

    Poništi
  6. proslijedio/la je Tweet

    Here we go: One Medical is set to start trading today after raising $245 million in its IPO

    Poništi
  7. proslijedio/la je Tweet

    : Stunning new numbers. Running totals - 9,171 confirmed cases worldwide vs 7,711 China cases yesterday; 213 deaths vs 130 yesterday. More than 12,000 suspected cases. 1,476 in serious or critical condition. ALL regions of China are reporting cases. h/t

    Prikaži ovu nit
    Poništi
  8. 30. sij

    Amgen's Herceptin and Avastin biosimilars posted $79M each in US sales for Q4. The co. says that represents 15% and 17% of the market, respectively

    Prikaži ovu nit
    Poništi
  9. 30. sij

    Amgen says it will exceed $1 billion in biosimilar sales for 2020. In 2019, they launched their first 2 in the US for Herceptin and Avastin Q4 45-slide presentation now live here:

    Prikaži ovu nit
    Poništi
  10. 30. sij

    Quite the IPO for Black Diamond Therapeutics — stock priced closed just under $40 today. Initially priced at $19.

    Poništi
  11. 30. sij

    While dodging most of today's questions on aducanumab, Biogen execs did give some updates Read more here on the re-dosing study and future combination therapies in Alzheimer's for :

    Poništi
  12. 30. sij

    Fascinating way to visually show the development timeline of drugs here, and how different policies affect the rewards ⬇️

    Poništi
  13. 30. sij

    Sandrock says Biogen built its Alz. pipeline with combination therapies in mind. He says the most obvious Alzheimer's combination to try is adding an anti-tau to aducanumab

    Prikaži ovu nit
    Poništi
  14. 30. sij

    The re-dosing study will be single arm, so main focus will be safety and tolerability. Sandrock likened it to an open-label extension — but also said they will look at efficacy as best as they can on biomarkers like amyloid.

    Prikaži ovu nit
    Poništi
  15. 30. sij

    Biogen's Al Sandrock says the company is running the aducanumab re-dosing study primarily for humanitarian reasons. "We felt we owed something to them [the patients]. Many of them expressed a desire to the investigators that they wanted the drug," he said

    Prikaži ovu nit
    Poništi
  16. 30. sij

    Biogen acknowledges the obvious: an impact from Zolgensma on Spinraza in the infant market. Says that represents 5% of the SMA market.

    Prikaži ovu nit
    Poništi
  17. 30. sij

    Biogen has also filed protocol to the FDA to start a re-dosing study of aducanumab. Now working with clinical sites and ethics committee to start running trial. Will be open to people previously enrolled in an aducanumab trial to start receiving the drug again.

    Prikaži ovu nit
    Poništi
  18. 30. sij

    CEO Michel Vounatsos on current status of aducanumab filing: "We are actively engaging with the FDA as well as regulators in Europe and Japan, and we look forward to completing a regulatory filing in the US as soon as possible."

    Prikaži ovu nit
    Poništi
  19. 30. sij

    Rubius has dosed the first patient in its PKU Phase 1 study. Reminder the timeline on this, maintained well into late 2019, was an early readout by end of last year. The biotech now isn't putting out a timeline on initial data. PR:

    Poništi
  20. 29. sij

    Novartis just laid out the playbook for making its $2.1 million gene therapy treatment a blockbuster. Here are the next steps:

    Poništi
  21. 29. sij

    The largest case study yet of coronavirus just published in The Lancet — 99 patients. About half were exposed to the Huanan seafood market -- 46 of the 99 worked at the market as managers or salespeople. Study here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·